51933
document
A controlled crossover trial of fenfluramine in autism . We report a 12 month double-blind randomized crossover trial of fenfluramine in 20 children with the syndrome of autism . On active drug most of the children lost weight and blood serotonin levels fell by an average of 60 % . There was a fall in urinary dopamine ( DA ) and noradrenaline ( NA ) levels and increased excretion of homovanillic acid ( HVA ) . Some of the children showed improvement in tests of cognitive and language function , although the results did not achieve overall statistical significance . Event-related brain potentials ( ERPs ) were obtained in seven subjects on an auditory choice reaction time task . Side effects of the drug included irritability and lethargy . Fenfluramine may have a limited place in the management of some patients with autistic disorder .
51934
Intervention_Pharmacological
fenfluramine
51935
Intervention_Pharmacological
fenfluramine
51936
Outcome_Physical
lost weight
51937
Outcome_Physical
blood serotonin levels
51938
Outcome_Physical
urinary dopamine ( DA )
51939
Outcome_Physical
noradrenaline ( NA ) levels
51940
Outcome_Physical
increased excretion of homovanillic acid ( HVA )
51941
Outcome_Mental
tests of cognitive and language function
51942
Outcome_Physical
Event-related brain potentials ( ERPs )
51943
Outcome_Adverse-effects
Side effects
51944
Outcome_Adverse-effects
irritability and lethargy
51945
Participant_Condition
autism
51946
Participant_Sample-size
20
51947
Participant_Age
children
51948
Participant_Condition
autism
51949
Participant_Age
children
51950
Participant_Age
children
51951
Participant_Condition
autistic